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Effects of antihypertensive drugs in experimental type 2 diabe- the hypothesis that proteinuria may be an independent
tes-related nephropathy. mediator of progression rather than simply a marker of
Background. It has been extensively reported that anti- glomerular dysfunction [2].hypertensive drugs reduce proteinuria and glomerulosclerosis
Angiotensin converting enzyme inhibitors (ACEIs)(GS) in many experimental nephropathies and in humans.
uniformly have been shown to prevent the developmentHowever, the role of calcium channel blockers (CCBs) in the
prevention of proteinuria and GS remains controversial and in of both proteinuria and glomerulosclerosis in diabetic rats
most cases only dihidropyridine-CCBs are studied. Few studies and humans [3, 4]. Calcium channel blockers (CCB) are
have reported whether the time at which drug administration being extensively used to treat systemic hypertension andis initiated plays a role in the reduction of proteinuria and GS.
to prevent renal damage. However, the role of CCBs inMethods. Fifty-six male Obese Zucker rats (OZR) were used
the prevention of proteinuria and GS in diabetic rats oras a model of spontaneous type 2 diabetes-related nephropathy.
Biochemical and histological analysis were performed to com- human subjects remains controversial, and only a few stud-
pare the efficacy of a non-dihydropyridine-CCB diltiazem [DZM; ies with dihidropyridine-CCBs have been published [5–7].
100 mg/kg body weight (BW)/day], an ACEI quinapril (10
Many reports have suggested that ACEIs act by amg/kg BW/day), or both in diminishing proteinuria and GS, and
hemodynamic mechanism (systemic blood pressure andto determine their role in effective prevention and treatment.
glomerular pressure) and by reducing proteinuria andResults. Only quinapril was able to diminish proteinuria. As
far as histological lesions, both treatments were effective, al- the expression of several cellular mediators [3, 4]. Several
though only quinapril prevented GS. The combination of quin- experimental studies have suggested that podocyte dam-
april plus DZM did not demonstrate any beneficial effects. age is involved in some progressive nephropathies [8].Surprisingly, quinapril ameliorated the damage of podocytes
There are, however, few in-depth studies on the filtrationwhereas DZM did not, thus leading to doubt concerning the
barrier and the effect drugs have on it [9, 10]. Few reportsefficiency of DZM in long-term studies. Nonetheless, the com-
bination of quinapril plus DZM demonstrated a greater reduc- have studied whether the time of initiation of the drug
tion in podocyte damage than treatment with DZM alone, plays a role in reducing proteinuria and GS, and whether
which shows an interesting association in the prevention of its efficacy is the same when administered as a preventa-longer-term glomerular damage. Few differences were found
tive or treatment.between prevention and treatment.
With this background we compared a non-dihydropyr-Conclusions. Quinapril, but not DZM, was able to diminish
proteinuria in OZR. Both treatments were effective in dimin- idine-CCB diltiazem (DZM), and ACEI quinapril or a
ishing GS, although only quinapril totally prevented it. The combination of both in diminishing proteinuria and GS,
combination of both drugs prevented long-term glomerular and studied their influence of podocyte damage in a spon-damage, which is intriguing.
taneous model of diabetic nephropathy, the Obese Zucker
rats (OZR) [11]. Moreover, we determined whether pre-
vention and treatment using both drugs had the sameDiabetic nephropathy is one of the major causes of
efficacy.end-stage renal disease around the world and it currently
represents one of the most important healthcare prob-
lems [1]. Several studies have shown a correlation be- METHODS
tween the degree of proteinuria, glomerulosclerosis (GS) Experimental animals and study procedures
and rate of progression of renal failure. This has led to
Eight-month-old male OZR were used. The rats were
obtained from IFFA CREDO (Lyon, France) and were
maintained in accordance with the Catalan Royal Decree.Key words: diabetic nephropathy, podocyte, glomerulosclerosis, ACE
inhibitors, calcium entry blockers, quinapril, diltiazem, proteinuria. During the study period, the rats were fed standard chow
(A04; Panlab, Barcelona, Spain) and water ad libitum. 2002 by the International Society of Nephrology
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Quinapril [10 mg/kg body weight (BW)/day] and DZM Statistical analysis
(100 mg/kg BW/day) were provided by Pfizer (Madrid, All results were expressed as mean  SEM and P 
Spain). 0.05 was considered statistically significant in every case.
The animals were randomly assigned into six groups. The Kolmogorov-Smirnov test and the Levene test were
The first group consisted of OZR (N  8) that had performed to assess population normality and the homo-
received quinapril since two months of age (prevention geneity of variances, respectively. The mean compari-
with quinapril; PQ). The second group consisted of OZR sons were performed by one-way analysis of variance
(N  8) that had received DZM since two months of (ANOVA) with contrast coefficients or the Kruskal-
age (prevention with DZM; PD). The third group con- Wallis test when appropriate. To test for associations
sisted of OZR (N 10) that had received quinapril since among the results, Pearson’s correlation coefficients
five months of age (treatment with quinapril; TQ). The were calculated. Linear multivariate regression also was
fourth group consisted of OZR (N  10) that had re- performed.
ceived DZM since five months of age (treatment with
DZM; TD). The fifth group consisted of OZR (N  10)
RESULTSthat had received quinapril and DZM since five weeks
of age (treatment with quinapril plus DZM; TQD). Fi- The body weights of the control rats were significantly
higher than that of the other groups. No statistical differ-nally, the control group consisted of OZR (N  10)
that did not receive any treatment. Rats receiving the ences were found among the treated groups. On the
other hand, obesity showed a significant correlation withtreatment at five months of age were found to have
marked proteinuria in comparison with the control group systolic blood pressure (SBP; r  0.379), glucose (r 
0.381) and GS (r  0.304). Serum glucose was also nota-(88  13 mg/day at month 5 vs. 84  9 mg/day at month
8, P  NS). ble in the control group compared to treatments, but did
not achieve a statistical difference (Table 1).All the rats were sacrificed at eight months. Once a
week, body weight was determined, while once a month Serum cholesterol levels were reduced with quinapril,
and no differences were found in serum triglycerides.the diuresis was assessed with a 24-hour urine collection;
systolic blood pressure (SBP) was established by the tail- Both treatments and their combination showed a dimi-
nution in SBP compared with the control group, particu-cuff method with a validated pressure monitor (LE-5001;
Letica Scientific Instruments, Barcelona, Spain). Fasting larly in the rats given quinapril treatment. Furthermore,
SBP was significantly correlated with proteinuria (r blood samples were obtained at the end of experiment
and biochemical studies (glucose, cholesterol, triglycer- 0.499), obesity (r  0.379), cholesterol (r  0.341) and
GS (r  0.299). On the other hand, creatinine in theides, creatinine and total proteins) were measured with
a clinical analyzer (Technicon Instruments, Tarrytown, control rats was higher than in the treated rats.
Finally, as we expected, proteinuria showed the high-NY, USA). The 24-hour urine samples and urine protein
concentrations (mg/day) were assessed by the Dimen- est value in the control group at the end of the study.
In the prevention and treatment with quinapril groupssion RxL Clinical Chemistry System (Dade, Newark,
NJ, USA) proteinuria diminished 95% and 89%, respectively. On
the other hand, the treatment with DZM only reduced
Morphological studies proteinuria in 26% compared to the control group (P 
NS). Similar results were obtained with the combinationThe frequency of focal and segmental glomerular scle-
rotic lesions (FSGS) was determined by examining all of drugs (reductions of 35%; Fig. 1).
glomerular profiles as the mean  SD of 100  10/
Morphological studiesanimals contained in a paraffin section from each kidney,
as Kasiske et al [12] and our group have described pre- Morphological evaluation of kidney tissue demon-
strated consistent glomerulosclerotic lesions in the con-viously [3].
trol group, involving 12% of glomeruli at the end of the
Desmin immunoperoxidase staining study. In both quinapril groups GS diminished, achieving
values close to 1% (nearly to normal) when comparedParaffin-embedded kidney sections (4 m) were pro-
cessed by indirect immunoperoxidase. Primary antibodies to the control group. On the other hand, both DZM
groups and the combination group showed lower reduc-were included for desmin (1/50; Dako, Glostrup, Den-
mark). The desmin results were evaluated in 100 glomer- tions in GS compared to then control group, although
they showed the same prevention of GS when compareduli per animal and were expressed as the mean of ratios
of desmin area versus tuft glomerular area for each glo- to each other (Fig. 1). Moreover, glomerulosclerotic le-
sions were significantly correlated with proteinuria (r merulus. The glomerular areas were determined by com-
puterized morphometry (Hamamatsu Photonics KN, 0.558) and to a lesser extent with obesity (r  0.304)
and SBP (r  0.299). Concerning their glomerular area,Hamamatsu-City, Japan).
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Table 1. Data for control, quinapril and diltiazem-treated rats at the end of the experimental period
Cholesterol Triglycerides Glucose
Body weight Creatinine Blood pressure
g mg/dL mmol/L mm Hg
Control (N  8) 6000 446 6.70.4 3.50.8 12.41 1502
QP (N  8) 52315a 362 5.60.2b 3.10.6 9.50.5 1394a,c
DP (N  8) 48419a 395 6.60.6c 40.9 8.60.5 1434
QDT (N  10) 4929a 342 7.20.3f 3.51 9.10.5 1422a,e
QT (N  10) 5118a 302a,d 5.70.3d 4.80.6 8.60.5 1252a,d
DT (N 10) 49613a 452 7.80.4 3.80.5 90.4 1373a
Data are mean  SEM. Abbreviations are: QP, prevention with quinapril; DP, prevention with diltiazem (DZM); QDT, treatment with quinapril plus DZM;
QT, treatment with quinapril; DT, treatment with DZM. Significance was determined using ANOVA where P between groups 0.05.
a Indicated values vs. control
b Q vs. control
c QP vs. QT
d DT vs. QT
e QDT vs. QT
f QD vs. DT
Fig. 1. Proteinuria, glomerulosclerotic lesions, and glomeruli staining desmin in the three groups at the end of the study. Values are given as
mean  SEM, and significance was determined using ANOVA. P between groups  0.05. Abbreviations are: QP, prevention with quinapril; DP,
prevention with diltiazem (DZM); QDT, treatment with quinapril plus DZM; QT, treatment with quinapril; DT, treatment with DZM; FGS
lesions, glomerulosclerotic lesions.
there were significant correlations with glucose (r  the second model the dependent variable was GS. The
0.376), desmin (r  0.306) and proteinuria (r  0.279). predictor for this model was proteinuria (  7.4 E-02,
P  0.000). Finally, in the last model performed, the
Desmin immunoperoxidase staining dependent variable was desmin and the predictors were
Concerning desmin intensity, both prevention and proteinuria (  2.6 E-03, P  0.034) and creatinine
treatment with quinapril achieved important statistical (  0.204, P  0.005).
diminutions compared to the control group; however,
no reductions were found in any DZM group. Interest-
DISCUSSIONingly, the combination of both drugs showed statistical
It has been extensively reported that a reduction inreductions (Fig. 1). Furthermore, a significant correlation
elevated arterial blood pressure (BP) diminishes protein-was found with proteinuria (r  0.384), creatinine (r 
uria and GS in many experimental nephropathies and0.365), glomerular area (r  0.306) and cholesterol (r 
in humans. This fact is especially important in diabetic0.307).
nephropathy, which is one of the major causes of end-
Linear multivariate regression analysis stage renal disease [1]. Thus, the control of BP attenuates
the progression of renal dysfunction and reduces mortal-In the first model, the dependent variable was protein-
ity, although it has been shown as a single factor [13].uria. The predictors were glucose (  7.6, P  0.000),
Several studies have shown a correlation between thecholesterol (  21.5, P  0.002), desmin (  3.8, P 
0.000), and GS (  6.1, P  0.000). Furthermore, in degree of proteinuria and rate of progression of renal
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failure, and that proteinuria may be an independent me- induced nearly a total reduction of proteinuria and GS,
whereas DZM maintained proteinuria with a lower effi-diator of progression [2]. ACEIs are considered to pre-
vent the development of both proteinuria and GS in cacy. Similar results have been described by Remuzzi and
colleagues [16] and Mifsud et al [18] in an experimentalexperimental diabetic models and in humans. However,
the renoprotective effects of the different types of CCBs model of progressive non-diabetic nephropathy and
streptozotocin diabetic rats in which late onset of ACEIhave not been clearly demonstrated and remain contro-
versial. Although the vast majority of data demonstrate had similar efficacy in arresting the progression of glo-
merular damage. On the other hand, our current studythat dihydropyridine-CCBs effectively reduce arterial
pressure, they do not significantly affect proteinuria nor does not agree with Podjarny et al [19], who determined
that IECAs (captopril) decreased the severity of GS anddo they prevent the development of glomerular scarring.
However, this issue remains under debate [5, 7]. proteinuria only if the drug was administrated immedi-
ately after surgery in uninephrectomized rats. We postu-Along this line, the first aim of our current study was
to compare the non-dihydropyridine-CCB, DZM, and late that this poor reduction in proteinuria with DZM
therapy shows that DZM may be unable to prevent glo-the ACEI, quinapril, in diminishing proteinuria and GS
in a spontaneous experimental model of type 2 diabetes- merular lesions in long-term studies.
In a previous study, we demonstrated that early podo-related nephropathy. In the present study, biological pa-
rameters show scarce differences, and GS was normal- cyte damage develops in Zucker obese nephropathy as
shown by the desmin marker (abstract; Blanco et al,ized by quinapril whereas DZM only reduced it (P 
0.05). Concerning BP, quinapril demonstrated a greater Congress of the ERA-EDTA, 2001, p 115). In the present
study, the control group was positive to desmin and quin-efficiency. Bakris and colleagues studied BP using con-
tinuous telemetric monitoring and found statistical dif- april prevented its expression by 50%. However, DZM
treatment not only did not diminish desmin, but ratherferences [14]. Quinapril normalized proteinuria whereas
DZM only reduced proteinuria (P  NS). increased it. As desmin expression in rats treated with
DZM may explain, in part, why proteinuria is not asAs other authors have already reported on unineph-
rectomized diabetic rats [15], the current findings in our reduced in this group, it suggests the previous hypothesis
that DZM in a longer study would not be capable ofspontaneous model of type 2 diabetes-related nephropa-
thy suggest that different antihypertensive regimens may preventing glomerular lesions. Along this line, several
studies have reported that ACEIs play a role in thenot prove to be equally effective in protecting the dia-
betic kidney: quinapril was found to be more effective glomerular barrier by diminishing heparan sulfate [20].
With respect to the effect of CCBs on the glomerularthan DZM. Multivariate regression analysis showed that
SBP was not relevant in the prediction of proteinuria. barrier, there are a number of other investigations that
affirm that CCBs act at the level of the membrane ultra-However, although we did not perform monitoring, some
authors consider that it is unlikely that BP reduction structural components [9, 10], although none refer to
glomerular damage.per se is the single factor responsible for amelioration of
protein filtration at a glomerular level [16]. However, Pod- These results are confirmed also with linear multivari-
ate regression studies in which proteinuria was predictedjarny et al found that DZM does not have favorably ef-
fects on the early course of adriamycin nephropathy [17]. by desmin and metabolic status, and GS was predicted by
proteinuria. Therefore, we speculate that proteinuria isMost studies have shown that early administration
with ACEIs reduces proteinuria and prevents GS. How- closely related to podocyte damage. This correlation is
very interesting if we consider that podocytes are one ofever, there are few studies in which the administration
is started after the glomerular lesion was already estab- the most important components of the glomerular barrier.
The last objective in the present study was to confirmlished. Therefore, our experiments were designed to start
the treatment at five months of age, a time when protein- the hypothesis that concomitant administration of quin-
april and DZM has a favorable effect in both proteinuriauria (a marker of early disease) had already developed
in the OZR. and in GS related to DZM administration alone. The
most important result in our current study was that theConcerning proteinuria, neither prevention nor treat-
ment with quinapril or DZM presented statistical differ- combination of drugs showed no additional reduction in
proteinuria and GS compared to the DZM therapy alone.ences. Similarly, glomerulosclerotic lesions showed simi-
lar glomerular injury when prevention and treatment However, we found that quinapril plus DZM achieved
a good reduction in desmin expression. These results par-were compared for each drug. Again, prevention and
treatment with quinapril were found to be more effective tially agree with Bakris et al’s study of 5/6-renal ablated
rat using amlodipine and benazepril therapy, affirmingthan treatment alone with DZM.
The results of our current study show that a three- that the combination therapy of an ACEI and CCB pro-
vided additional protection against renal injury comparedmonth therapy with quinapril and DZM initiated a de-
crease in GS and proteinuria. Quinapril, in particular, to that provided by dihydropyridine-CCB alone [14]. We
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of effects by calcium-channel blockers. Nephrol Dial Transplantonly found podocyte protection and, therefore, only can
12:2244–2250, 1997
speculate that the combination of drugs leads to a de- 6. Griffin K, Picken MM, Bakris GL, Bidani AK: Class differences
in the effects of calcium channel blockers in the rat remnant kidneycrease in podocyte damage and glomerular protection
model. Kidney Int 55:1849–1860, 1999in long-term studies.
7. The PROCOPA Study Group: Dissociation between blood pres-
In conclusion, only quinapril—but not DZM—was sure reduction and fall in proteinuria in primary renal disease: A
randomized double-blind trial. J Hypertens 20:729–737, 2002able to diminish proteinuria. With regard to GS, both
8. Coimbra TM, Janssen U, Gro¨ne HJ, et al: Early events leadingtreatments were efficient although only quinapril totally
to renal injury in obese Zucker (fatty) rats with type II diabetes.
prevented GS. No beneficial effect was shown with the Kidney Int 57:167–182, 2000
9. Jyothirmayi GN, Reddi AS: Effect of diltiazem on glomerularcombination of quinapril plus DZM treatment. Quin-
heparan sulfate and albuminuria in diabetic rats. Hypertension 21:april ameliorated podocyte damage, whereas no reduc-
795–802, 1993
tion was observed with DZM, making its long-term effi- 10. Smith AC, Toto R, Bakris GL: Differential effects of calcium
channel blockers on size selectivity or proteinuria in diabetic glo-cacy doubtful. Nonetheless, the combination of both
merulopathy. Kidney Int 54:889–896, 1998drugs may reduce podocyte damage, which shows an 11. O’Donnell MP, Kasiske BL, Kim Y, et al: Lovastatin retards the
interesting association to prevent glomerular damage progression of established glomerular disease in Obese Zucker
rats. Am J Kidney Dis 22:83–89, 1993over a longer term. Few differences were found between
12. Kasiske BL, O’Donnell MP, Cleary MP, Keane WF: Treatmentprevention and treatment. of hyperlipidemia reduces glomerular injury in obese Zucker rats.
Kidney Int 33:667–672, 1988
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